Share class: Evotec SE

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A1177,909,559159,960,144 ( 89.91 %) 215,000 ( 0.1208 %) 89.91 %

Major shareholders: Evotec SE

NameStocks%Valuation
Excalibur Luxco SARL
9.966 %
17,730,913 9.966 % 67 M €
Goldman Sachs International (Invt Mgmt)
8.612 %
15,321,361 8.612 % 58 M €
MAK Capital One LLC
7.128 %
12,681,898 7.128 % 48 M €
Mubadala Investment Co. (Investment Company)
6.454 %
11,481,502 6.454 % 43 M €
Goldman Sachs Asset Management LP
5.652 %
10,055,638 5.652 % 38 M €
Goldman Sachs & Co. LLC (Private Banking)
5.03 %
8,948,625 5.03 % 34 M €
T. Rowe Price International Ltd.
4.568 %
8,127,117 4.568 % 31 M €
Black Creek Investment Management, Inc.
3.127 %
5,563,329 3.127 % 21 M €
Connor, Clark & Lunn Investment Management Ltd.
2.89 %
5,141,392 2.89 % 19 M €
Paladin Invest GmbH
0.1686 %
300,000 0.1686 % 1 M €
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
NameStocks%Valuation
DCF Advisers LLC
1.213 %
1,079,024 1.213 % 2 M €
WCM Investment Management LLC
0.7553 %
671,884 0.7553 % 1 M €
0.4181 %
371,936 0.4181 % 699 240 €
Optiver Holding BV
0.3622 %
322,153 0.3622 % 605 648 €
Morgan Stanley Capital Services LLC
0.2313 %
205,763 0.2313 % 386 834 €
LPL Financial LLC
0.1867 %
166,045 0.1867 % 312 165 €
Envestnet Asset Management, Inc.
0.1569 %
139,596 0.1569 % 262 440 €
Old Mission Capital LLC
0.0428 %
38,032 0.0428 % 71 500 €
Advisor Partners II LLC
0.0402 %
35,779 0.0402 % 67 265 €
Fore Capital LLC
0.0352 %
31,355 0.0352 % 58 947 €
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional44.41%
Others9.97%
Individuals0.2%
Unknown45.43%

Based on 1000 largest holdings

Geographical origin of shareholders

United States
17.81%
United Kingdom
13.21%
Germany
10.58%
United Arab Emirates
6.45%
Canada
6.02%
Individuals
0.2%
France
0.13%
Austria
0.07%
Spain
0.05%
Luxembourg
0.05%
Ireland
0.01%

Based on 1000 largest holdings

Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!